Frequently Asked Questions

Pepvela is a biology-first peptide research and education platform. It is designed to help individuals understand peptide compound categories, prepare appropriately before exploring any research protocol, evaluate stacking safety, and build informed discussion points for conversations with a licensed healthcare provider.

Pepvela does not prescribe peptides, sell products, or provide medical advice. All content on this platform is for educational and research reference purposes only. Peptide compounds referenced on this platform are not FDA-approved for human therapeutic use in most cases and are presented strictly as research compounds.

No account is required. All educational content , the Peptide Finder, Lab Guide, Safety Checker, Protocol Builder, Injection Guide, and all library pages , is accessible without registration. Pepvela is not a subscription service and has no products to sell.

Access to organized, evidence-referenced research information should not require a credit card. The educational layer of Pepvela is a permanent public resource.

No. Pepvela is designed to be accessible to everyone from complete beginners to practicing clinicians. The tools and content are written at two levels simultaneously: plain language for those new to peptide research, and mechanism-level detail for physicians and advanced researchers who want clinical context.

That said, Pepvela strongly encourages all users , regardless of background , to work with a licensed healthcare provider before acting on any information presented here. The platform is a research and education reference, not a replacement for clinical guidance.

Start with the Lab Guide, which explains the Pepvela framework and the "Test Before You Stack" philosophy , the idea that understanding your baseline biology should always come before exploring any research compound.

From there, try the Peptide Finder, which asks structured questions about your goals, symptoms, and health context to generate a biology-matched research profile. The Lab Guide will then tell you which baseline biomarkers are relevant to review before going further. This three-step sequence , framework, profile, labs , is the recommended starting point for all new users.

Pepvela's content is written with reference to published research literature and organized to clearly reflect the actual evidence landscape. We use a four-level evidence badge system , Established, Moderate Evidence, Emerging Evidence, Insufficient Human Evidence , on all peptide and biomarker content to reflect how well-studied each compound actually is.

Pepvela is not a substitute for consultation with a licensed healthcare provider. Research literature reflects outcomes observed in specific study populations under controlled conditions, which may not apply to your individual biology, health history, or concurrent medications. All content is for educational purposes only.

A peptide is a short chain of amino acids , the same building blocks that make up proteins. In the body, endogenous peptides act as signaling molecules that trigger specific biological processes: stimulating hormone release, promoting tissue repair signaling, modulating immune activity, or influencing metabolic pathways.

Research peptides are synthetic analogs of these naturally occurring signaling molecules, studied in laboratory and clinical settings for their ability to replicate or modulate specific physiological responses. Most research peptides referenced on this platform are not FDA-approved for human therapeutic use and are studied in research contexts. Always consult a licensed healthcare provider before considering any peptide compound.

The safety profile of any research peptide is context-dependent and varies significantly between compounds. Some peptides have decades of preclinical and clinical research behind them; others are primarily studied in preclinical research with limited published human data. Research does not equal safety for human use.

Risk factors that affect safety profile include: the specific compound and its mechanism of action, the individual's existing health conditions and biomarker levels, concurrent medications and potential interactions, the source and purity of the compound, and dosing parameters studied in available literature.

Pepvela's evidence badge system reflects the strength of available research , not a safety endorsement. The Stacking Safety Checker flags known interaction risks. Neither replaces clinical evaluation by a qualified physician who can assess your individual risk profile.

"Stacking" refers to the concurrent use of two or more research peptides. Research literature on peptide combinations is significantly more limited than research on individual compounds , most combination data comes from anecdotal reports, case studies, or theoretical mechanistic reasoning rather than controlled trials.

Some combinations have a plausible complementary mechanism with no documented adverse interaction , for example, research on BPC-157 and TB-500 together in tissue repair contexts, or Ipamorelin combined with CJC-1295 for GH axis research. Other combinations carry documented or theoretically significant risks: stacking two GLP-1 agonists (such as semaglutide and tirzepatide) presents overlapping mechanisms with no research basis for added benefit and significant risk of adverse effects.

The Stacking Safety Checker on Pepvela evaluates known interaction data for peptide-peptide and peptide-medication pairs. Physician oversight is considered essential before any combination research protocol is considered.

Pepvela's Peptide Finder is structured specifically for this purpose. It asks about your research goals, current symptoms, health history, medications, and available lab results, then generates a biology-matched profile describing which peptide categories research literature associates with your goal set , and which baseline biomarkers you should review before researching further.

The Finder does not tell you to use any specific peptide. It tells you what the research landscape suggests may be relevant given your reported biology, what information is missing, and what questions to bring to a licensed healthcare provider. Research-goal alignment and individual biological context are two different things , the Finder helps you understand both before making any decisions.

Published research on peptide administration windows varies significantly by compound and research context. General patterns observed in available literature:

• Tissue repair compounds (e.g., BPC-157, TB-500): research commonly documents 4–12 week administration windows
• GH secretagogue compounds (e.g., Ipamorelin, CJC-1295): research protocols commonly describe 12–24 week cycles with off-cycle periods
• Longevity-focused compounds (e.g., Epithalon): traditional research designs often use short, infrequent courses (e.g., 10-day protocols repeated 1–2 times per year)
• Immune-modulating compounds (e.g., Thymosin Alpha-1): protocols vary widely based on the research context and indication studied

These patterns reflect what has been studied in research literature, not clinical treatment recommendations. The Protocol Builder helps organize a cycle structure for clinician review , it is a planning and documentation tool, not a prescription.

Peptide compounds interact with your existing biological systems , not a theoretical average. Research outcomes observed in study populations reflect population averages, not individual baseline status. Without baseline biomarkers:

• You cannot detect whether a compound is having any measurable effect on the intended pathway
• You cannot identify early warning indicators of adverse biological response
• You cannot determine whether your individual biomarker levels make you a reasonable research candidate for a given compound category
• You cannot have a clinically meaningful conversation with a physician about your research context

For example, GH secretagogue research looks very different depending on whether your baseline IGF-1 is in the lower quartile or already elevated. The same compound at the same dose in the same individual produces different biological outcomes depending on baseline context. Pepvela's Lab Guide identifies which specific biomarkers are most relevant for each peptide category under research consideration.

The specific biomarkers depend on which peptide category you are researching. The Lab Guide organizes recommended baseline panels by goal, symptom cluster, and peptide category. General baseline recommendations by category include:

• Any peptide protocol: CMP (comprehensive metabolic panel), CBC (complete blood count), hs-CRP (inflammatory baseline)
• GH secretagogue research (Ipamorelin, CJC-1295, Sermorelin): IGF-1, fasting insulin, fasting glucose, HbA1c
• GLP-1 agonist research (Semaglutide, Tirzepatide): liver enzymes (ALT, AST), kidney function (creatinine, eGFR), lipase, HbA1c
• Immune-modulating research (Thymosin Alpha-1): CBC with differential, autoimmune markers if indicated
• Hormonal context: testosterone (total + free), estradiol, SHBG, TSH, Free T3/T4 where relevant

These are research-context recommendations, not medical advice. A licensed healthcare provider can advise on which specific panels are appropriate for your individual circumstances.

In the United States, direct-to-consumer (DTC) laboratory services allow individuals to order specific bloodwork panels without a physician's order. Services commonly used for this purpose include LabCorp OnDemand, Quest Diagnostics MyQuest, Ulta Lab Tests, and similar platforms. Results typically return within 1–3 business days.

Important note: obtaining lab results without a clinical interpretation context does not replace physician guidance. A biomarker outside the reference range carries very different clinical implications depending on the individual's full health picture, age, sex, and other concurrent values. Pepvela strongly recommends that all lab results be reviewed with a licensed healthcare provider, even if obtained independently.

The availability and legality of direct-to-consumer testing varies by state. Always verify what is available in your location.

Retesting cadence depends on the compound category and research protocol length. General patterns from research literature and clinical practice guidelines:

• For active research protocols: midpoint testing (4–6 weeks) and end-of-cycle testing gives meaningful before/after data
• GH secretagogue protocols: IGF-1, fasting glucose, and fasting insulin should be rechecked at 4–8 weeks due to the impact on insulin sensitivity
• Longer protocols (12+ weeks): quarterly lab panels are a reasonable standard to track biological response and detect early signals
• Between cycles: a washout period lab panel helps establish a restored baseline before beginning a new cycle

The Lab Guide includes retesting cadence recommendations for each peptide category. A supervising physician can advise on appropriate intervals based on your individual response and health context.

The Peptide Finder is a structured quiz that builds a biology profile based on your research goals, reported symptoms, health history, current medications, and available lab results. Based on that profile, it identifies which peptide categories research literature associates with your goals, explains why they may be relevant, and flags which baseline biomarkers or safety considerations are missing from your picture.

The Peptide Finder does not prescribe or recommend specific compounds for human use. It is a research reference tool that maps your reported biology to relevant research literature and tells you what additional information you need before having a clinically meaningful conversation with a healthcare provider. The output is explicitly framed as a research starting point, not a clinical recommendation.

The Protocol Builder is a planning and documentation tool that helps organize a research protocol schedule , including compounds under consideration, cycle length, timing windows, and administration notes , in a structured, exportable format.

The primary purpose of the Protocol Builder is to create a document you can bring to a licensed healthcare provider for review and discussion. It is not a prescription tool and does not provide dosing guidance. Dosing parameters for any research compound should be determined by a qualified clinician with access to your full health history and baseline labs, not by a planning application.

The Stacking Safety Checker is an interactive reference tool that evaluates known or theoretically significant interaction risks for peptide-peptide and peptide-medication combinations. Select two or more compounds to see the available interaction profile , whether research literature and mechanistic reasoning suggest the combination is compatible, requires caution, or carries significant risk.

The medication checker allows you to type a current medication and see which peptide categories have documented or potential conflicts with it, with plain-language explanations of the underlying mechanism.

The Safety Checker reflects available research data and mechanistic reasoning , it does not guarantee safety. Many peptide combinations have no meaningful published interaction data. "Insufficient data" is not the same as "safe." All combination decisions should be reviewed with a physician who can assess your complete health profile.

Most peptide information sources fall into one of three categories: academic research papers that are technically rigorous but inaccessible without a scientific background; community forums and discussion boards that lack clinical context, safety grounding, and evidence grading; or content produced by supplement or compound suppliers that have a commercial interest in the information they present.

Pepvela is structured to be none of those things:

• No product to sell. Pepvela generates no revenue from peptide compound sales. There is no commercial incentive behind any content on this platform.
• Evidence-graded content. Every peptide and biomarker page uses the four-level evidence badge system to reflect the actual strength of available research , not marketing language.
• Biology-first framework. The "Test Before You Stack" philosophy means every tool is designed to encourage baseline lab testing and clinical oversight before research action, not after.
• Safety is the first tool, not an afterthought. The Stacking Safety Checker is one of the platform's core features , not a footnote.
• Accessible to everyone. Plain language and mechanism-level detail coexist on the same pages, serving both new researchers and clinicians from the same interface.